George Bakris
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1821021619
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $282,956 of the $402,814 with a category attached, or 70.2%. 32 manufacturers reported payments, led by Bayer at 34.3% of the total. Reporting peaked in 2019 at $154,528 and has fallen 95.0% since, to $7,710 in 2024. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $1122.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$138K
- Sanofi-aventis U.S. LLC$39K
- Novo Nordisk$35K
- Merck$24K
- AstraZeneca$21K
- Johnson & Johnson$19K
- plus $127K from 26 others
Across 18 payments — averaging $3827.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$34K
- AbbVie$23K
- Janssen Scientific Affairs, LLC$7K
- Janssen Research & Development, LLC$3K
- Bayer$2K
- Merck$593
What the payments were for
- Consulting fees$282,95670%
- Speaking & faculty fees$49,35712%
- Travel & lodging$62,32915%
- Food & beverage$8,1302%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 126 | $138,351 |
| Sanofi-aventis U.S. LLC | 11 | $38,915 |
| Novo Nordisk | 40 | $35,371 |
| Merck | 27 | $23,555 |
| AstraZeneca | 32 | $20,709 |
| Johnson & Johnson | 13 | $18,869 |
| Janssen Scientific Affairs, LLC | 11 | $17,390 |
| Astrazeneca UK Limited | 9 | $15,123 |
| Novo Nordisk AS | 9 | $14,315 |
| Alnylam Pharmaceuticals Inc. | 9 | $12,540 |
| Vifor Pharma, Inc. | 18 | $11,986 |
| Janssen Research & Development, LLC | 9 | $9,904 |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | 2 | $6,394 |
| Gilead | 2 | $5,110 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 3 | $4,909 |
| Janssen Global Services, LLC | 2 | $4,738 |
| Ardelyx, Inc. | 1 | $4,600 |
| Boehringer Ingelheim International GmbH | 4 | $3,310 |
| UCB SA | 3 | $3,203 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,720 |
| Esperion Therapeutics, Inc. | 10 | $2,578 |
| Amgen | 1 | $2,075 |
| CSL Behring | 1 | $2,043 |
| Medtronic(2 entities) | 3 | $1,785 |
| F. Hoffmann-la Roche AG | 1 | $1,120 |
| Genentech, Inc. | 1 | $745 |
| Calliditas Therapeutics US Inc. | 1 | $104 |
| Astrazeneca AB | 3 | $91 |
| Lexicon Pharmaceuticals, Inc. | 1 | $88 |
| Boehringer Ingelheim | 2 | $77 |
| Fresenius USA Marketing, Inc. | 1 | $52 |
| Travere Therapeutics, Inc. | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$81,909
- Non-Covered$58,395
- AVAPRO$28,507
- Victoza$26,930
- INVOKANA$26,134
- Veltassa$15,963
- FARXIGA$10,625
- NO PRODUCT DISCUSSED$10,312
- MICARDIS$6,394
- LOKELMA$5,480
- JARDIANCE$3,310
- NEXLETOL$2,392
- NEXLIZET$2,392
- KRYSTEXXA$2,075
- Non-Covered Product$1,865
- Levemir$228
- NovoLog$228
- NovoLog Mix 70/30$228
- XARELTO$124
- TARPEYO$104
How this compares
$402,814 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 11 | $896 |
| Amlodipine Besylate | 32 | $223 |
| Olmesartan Medoxomil | 18 | $197 |
| Carvedilol | 17 | $157 |
| Spironolactone | 13 | $116 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
- Hong LeeChicago$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.